Zürcher G - Search Results

1

Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.

Napolitano A, Bellini G, Borroni E, Zürcher G, Bonuccelli U. Napolitano A, et al. Among authors: zurcher g. Parkinsonism Relat Disord. 2003 Jan;9(3):145-50. doi: 10.1016/s1353-8020(02)00016-0. Parkinsonism Relat Disord. 2003. PMID: 12573869

2

Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity.

Lerner C, Masjost B, Ruf A, Gramlich V, Jakob-Roetne R, Zürcher G, Borroni E, Diederich F. Lerner C, et al. Among authors: zurcher g. Org Biomol Chem. 2003 Jan 7;1(1):42-9. doi: 10.1039/b208690p. Org Biomol Chem. 2003. PMID: 12929389

3

Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy.

Jorga KM, Fotteler B, Heizmann P, Zürcher G. Jorga KM, et al. Among authors: zurcher g. Eur J Clin Pharmacol. 1998 Jul;54(5):443-7. doi: 10.1007/s002280050490. Eur J Clin Pharmacol. 1998. PMID: 9754991 Clinical Trial.

4

Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans.

Zürcher G, Da Prada M, Dingemanse J. Zürcher G, et al. Biomed Chromatogr. 1996 Jan-Feb;10(1):32-6. doi: 10.1002/(SICI)1099-0801(199601)10:1<32::AID-BMC550>3.0.CO;2-N. Biomed Chromatogr. 1996. PMID: 8821869

5

Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.

Napolitano A, Zürcher G, Da Prada M. Napolitano A, et al. Among authors: zurcher g. Eur J Pharmacol. 1995 Feb 6;273(3):215-21. doi: 10.1016/0014-2999(94)00682-w. Eur J Pharmacol. 1995. PMID: 7737328

6

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.

Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T, van Brummelen P. Dingemanse J, et al. Among authors: zurcher g. Eur J Clin Pharmacol. 1996;50(1-2):47-55. doi: 10.1007/s002280050068. Eur J Clin Pharmacol. 1996. PMID: 8739811 Clinical Trial.

7

Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, Van Brummelen P. Dingemanse J, et al. Among authors: zurcher g. Br J Clin Pharmacol. 1995 Sep;40(3):253-62. doi: 10.1111/j.1365-2125.1995.tb05781.x. Br J Clin Pharmacol. 1995. PMID: 8527287 Free PMC article. Clinical Trial.

8

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.

Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, van Brummelen P. Dingemanse J, et al. Among authors: zurcher g. Clin Pharmacol Ther. 1995 May;57(5):508-17. doi: 10.1016/0009-9236(95)90035-7. Clin Pharmacol Ther. 1995. PMID: 7768073 Clinical Trial.

9

Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT).

Masjost B, Ballmer P, Borroni E, Zürcher G, Winkler FK, Jakob-Roetne R, Diederich F. Masjost B, et al. Among authors: zurcher g. Chemistry. 2000 Mar 17;6(6):971-82. doi: 10.1002/(sici)1521-3765(20000317)6:6<971::aid-chem971>3.0.co;2-0. Chemistry. 2000. PMID: 10785817

10

Monoclonal antibodies recognizing both soluble and membrane bound catechol-O-methyltransferase.

Bertocci B, Garotta G, Zürcher G, Miggiano V, Da Prada M. Bertocci B, et al. Among authors: zurcher g. J Neural Transm Suppl. 1990;32:369-74. doi: 10.1007/978-3-7091-9113-2_50. J Neural Transm Suppl. 1990. PMID: 2089101

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results